aTyrPharma, Inc. Stockholders with Large Losses are Encouraged to Contact Robbins LLP for Information About the Class Action Against ATYR

Core Viewpoint - aTyrPharma, Inc. is facing a class action lawsuit due to allegations of misleading investors regarding the efficacy of its drug candidate, Efzofitimod, during a clinical trial for pulmonary sarcoidosis [1][2]. Group 1: Allegations and Study Results - The lawsuit claims that aTyr's executives provided misleading information about the Phase 3 study's design and the drug's ability to allow patients to taper off steroids completely [2]. - On September 15, 2025, aTyr announced that the EFZO-FIT study did not meet its primary endpoint, specifically the change from baseline in mean daily OSC dose at week 48 [3]. - Following the announcement, aTyr's stock price plummeted from $6.03 per share on September 12, 2025, to $1.02 per share on September 15, 2025, marking an 83.2% decline in a single day [3]. Group 2: Legal Proceedings - Shareholders interested in participating in the class action must submit their papers to the court by December 8, 2025, to serve as lead plaintiff [4]. - The lead plaintiff will represent other class members in directing the litigation, but participation is not required to be eligible for recovery [4].